Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia September 3, 2019 - NASDAQ Companies 0 » View More News for September 03, 2019
